MedTrace Logo

CNTF Implants for CNGB3 Achromatopsia

NCT01648452 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-11-21

Study results available
· View outcomes & findings →

Summary

Background:

* Achromatopsia is an inherited condition that causes vision loss because cells in the retina do not work properly. It causes loss of acuity, sensitivity to light, and loss of color vision. There are no effective treatments for achromatopsia.
* Four genes currently are known to cause achromatopsia. One of these, the cyclic nucleotide-gated channel beta 3 (CNGB3) gene, is the cause in about 50 percent of people.
* CNTF is a natural chemical found in the body that promotes survival and function of nerve cells. CNTF has been shown to be effective in treating retinal disease in animals and can slow vision loss.
* CNTF has also been studied in over 250 people with retinal disease other than achromatopsia. In these studies, a CNTF implant was placed into the eye during a simple surgery. The implant releases CNTF inside the eye, near the retina. These studies suggested that a CNTF implant might help vision in some eye diseases.

Objectives:

* To learn whether a CNTF implant is safe for people with CNGB3 achromatopsia.
* To learn whether CNTF can improve visual acuity or color vision, and whether it may reduce sensitivity to light in people with CNGB3 achromatopsia.

Eligibility:

You may be able to take part in this study if you:

* Are at least 18 years old.
* Test positive for mutations in the CNGB3 gene and have no mutations in another achromatopsia gene.
* Have 20/100 vision or worse in at least one eye.
* Are not pregnant or nursing.

Design:

* To determine if you can take part, we will ask about your medical history and do a physical examination and an eye examination. Blood and urine samples will be taken.
* This study requires 11 visits to the National Eye Institute over 3 years.
* One visit will be for the implant surgery. The implant will be placed in one eye only.
* Study visits will take place 1 day after implant surgery, and again 1 week later and 1 month, 3 months, 6 months, 1 year, 1.5 years and 3 years later. These visits will help us evaluate the safety and benefit of the implant on your eye.
* At the 3 year visit, you can choose to keep the CNTF implant in your eye, or you can have us remove it.

Conditions

  • Eye Disease
  • Achromatopsia

Interventions

BIOLOGICAL

NT-501 CNTF-releasing implant

20 ng/day released into the eye

Sponsors & Collaborators

  • National Eye Institute (NEI)

    lead NIH

Principal Investigators

  • Paul A Sieving, MD, PhD · National Eye Institute (NEI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-03-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648452 on ClinicalTrials.gov